Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics

Archives of Pharmacal Research

Volumn 36, Issue 3, 2013, Pages 252-263

  Nguyen, Minh Phuong ^a   Lee, Sangkyu ^a   Lee, You Mie ^a  

^a Kyungpook National University   (South Korea)

Author keywords

DNA methylation; Epigenetics; Histone modification; Hypoxia inducible factor; microRNAs

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; DNA METHYLTRANSFERASE INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; MICRORNA; SMALL INTERFERING RNA; ZEBULARINE;

DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE CONTROL; HISTONE MODIFICATION; HUMAN; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; RNA INTERFERENCE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84879556042     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0058-x     Document Type: Review

References (147)

1. Alleman, W.G., R.L. Tabios, G.V. Chandramouli, O.N. Aprelikova, C. Torres-Cabala, A. Mendoza, C. Rogers, N.A. Sopko, W.M. Linehan, and J.R. Vasselli. 2004. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clinical Cancer Research 10: 7011-7021.
2. Antequera, F., and A. Bird. 1993. Number of CpG islands and genes in human and mouse. Proceedings of the National Academy of Sciences of the United States of America 90: 11995-11999.
3. Bacon, A.L., S. Fox, H. Turley, and A.L. Harris. 2007. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene 26: 132-141.
4. Benetatos, L., A. Dasoula, N. Syed, E. Hatzimichael, T. Crook, and K.L. Bourantas. 2008. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia 22: 1293-1295.
5. Berger, S.L. 2007. The complex language of chromatin regulation during transcription. Nature 447: 407-412.
6. Bernstein, E., A.A. Caudy, S.M. Hammond, and G.J. Hannon. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366.
7. Berra, E., E. Benizri, A. Ginouves, V. Volmat, D. Roux, and J. Pouyssegur. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO Journal 22: 4082-4090.
8. Bird, A.P. 1986. CpG-rich islands and the function of DNA methylation. Nature 321: 209-213.
9. Birner, P., M. Schindl, A. Obermair, G. Breitenecker, and G. Oberhuber. 2001. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clinical Cancer Research 7: 1661-1668.
10. Birner, P., M. Schindl, A. Obermair, C. Plank, G. Breitenecker, and G. Oberhuber. 2000. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Research 60: 4693-4696.
11. Bogdanovic, O., and G.J. Veenstra. 2009. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 118: 549-565.
12. Brugarolas, J.B., F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4: 147-158.
13. Bruick, R.K. 2000. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proceedings of the National Academy of Sciences of the United States of America 97: 9082-9087.
14. Carrero, P., K. Okamoto, P. Coumailleau, S. O'brien, H. Tanaka, and L. Poellinger. 2000. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Molecular and Cellular Biology 20: 402-415.
15. Chandel, N.S., E. Maltepe, E. Goldwasser, C.E. Mathieu, M.C. Simon, and P.T. Schumacker. 1998. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proceedings of the National Academy of Sciences of the United States of America 95: 11715-11720.
16. Chen, C., J. Wang, R. Liu, and S. Qian. 2012. RNA interference of hypoxia-inducible factor-1 alpha improves the effects of transcatheter arterial embolization in rat liver tumors. Tumour Biology 33: 1095-1103.
17. Chim, C.S., R. Liang, and Y.L. Kwong. 2002. Hypermethylation of gene promoters in hematological neoplasia. Hematological Oncology 20: 167-176.
18. Choudhary, C., C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen, and M. Mann. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
19. Clifford, S.C., A.H. Prowse, N.A. Affara, C.H. Buys, and E.R. Maher. 1998. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes, Chromosomes & Cancer 22: 200-209.
20. Clouaire, T., and I. Stancheva. 2008. Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? Cellular and Molecular Life Sciences 65: 1509-1522.
21. De Angelis, P.M., B. Fjell, K.L. Kravik, T. Haug, S.H. Tunheim, W. Reichelt, M. Beigi, O.P. Clausen, E. Galteland, and T. Stokke. 2004. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. International Journal of Oncology 24: 1279-1288.
22. Dmitriev, A.A., V.I. Kashuba, K. Haraldson, V.N. Senchenko, T.V. Pavlova, A.V. Kudryavtseva, E.A. Anedchenko, G.S. Krasnov, I.V. Pronina, V.I. Loginov, T.T. Kondratieva, T.P. Kazubskaya, E.A. Braga, S.P. Yenamandra, I. Ignatjev, I. Ernberg, G. Klein, M.I. Lerman, and E.R. Zabarovsky. 2012. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 7: 502-513.
23. Encode-Project-Consortium The ENCODE (ENCyclopedia Of DNA Elements) Project. 2004. Science 306: 636-640.
24. Epstein, A.C., J.M. Gleadle, L.A. Mcneill, K.S. Hewitson, J. O'rourke, D.R. Mole, M. Mukherji, E. Metzen, M.I. Wilson, A. Dhanda, Y.M. Tian, N. Masson, D.L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P.H. Maxwell, C.W. Pugh, C.J. Schofield, and P.J. Ratcliffe. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
25. Erkan, M., J. Kleeff, I. Esposito, T. Giese, K. Ketterer, M.W. Buchler, N.A. Giese, and H. Friess. 2005. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24: 4421-4432.
26. Fath, D.M., X. Kong, D. Liang, Z. Lin, A. Chou, Y. Jiang, J. Fang, J. Caro, and N. Sang. 2006. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. Journal of Biological Chemistry 281: 13612-13619.
27. Forstemann, K., Y. Tomari, T. Du, V.V. Vagin, A.M. Denli, D.P. Bratu, C. Klattenhoff, W.E. Theurkauf, and P.D. Zamore. 2005. Normal microRNA maturation and germ-line stem cell maintenance requires Loquacious, a double-stranded RNA-binding domain protein. PLoS Biology 3: e236.
28. Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16: 4604-4613.
29. Gao, L., M.A. Cueto, F. Asselbergs, and P. Atadja. 2002. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. Journal of Biological Chemistry 277: 25748-25755.
30. Gardiner-Garden, M., and M. Frommer. 1987. CpG islands in vertebrate genomes. Journal of Molecular Biology 196: 261-282.
31. Ghosh, A.K., T.D. Shanafelt, A. Cimmino, C. Taccioli, S. Volinia, C.G. Liu, G.A. Calin, C.M. Croce, D.A. Chan, A.J. Giaccia, C. Secreto, L.E. Wellik, Y.K. Lee, D. Mukhopadhyay, and N.E. Kay. 2009. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 113: 5568-5574.
32. Gibney, E.R., and C.M. Nolan. 2010. Epigenetics and gene expression. Heredity (Edinb) 105: 4-13.
33. Gnarra, J.R., G.M. Glenn, F. Latif, P. Anglard, M.I. Lerman, B. Zbar, and W.M. Linehan. 1993. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urologic Clinics of North America 20: 207-216.
34. Goll, M.G., F. Kirpekar, K.A. Maggert, J.A. Yoder, C.L. Hsieh, X. Zhang, K.G. Golic, S.E. Jacobsen, and T.H. Bestor. 2006. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 311: 395-398.
35. Gregoretti, I.V., Y.M. Lee, and H.V. Goodson. 2004. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. Journal of Molecular Biology 338: 17-31.
36. Gregory, R.I., K.P. Yan, G. Amuthan, T. Chendrimada, B. Doratotaj, N. Cooch, and R. Shiekhattar. 2004. The Microprocessor complex mediates the genesis of microRNAs. Nature 432: 235-240.
37. Grewal, S.I. 2010. RNAi-dependent formation of heterochromatin and its diverse functions. Current Opinion in Genetics & Development 20: 134-141.
38. Grewal, S.I., and D. Moazed. 2003. Heterochromatin and epigenetic control of gene expression. Science 301: 798-802.
39. Gu, Y.Z., S.M. Moran, J.B. Hogenesch, L. Wartman, and C.A. Bradfield. 1998. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expression 7: 205-213.
40. Guo, H., N.T. Ingolia, J.S. Weissman, and D.P. Bartel. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
41. Guo, L., L. Li, W. Wang, Z. Pan, Q. Zhou, and Z. Wu. 2012. Mitochondrial reactive oxygen species mediates nicotine-induced hypoxia-inducible factor-1alpha expression in human non-small cell lung cancer cells. Biochimica et Biophysica Acta 1822: 852-861.
42. Guzy, R.D., B. Hoyos, E. Robin, H. Chen, L. Liu, K.D. Mansfield, M.C. Simon, U. Hammerling, and P.T. Schumacker. 2005. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metabolism 1: 401-408.
43. Hamilton, A.J., and D.C. Baulcombe. 1999. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286: 950-952.
44. Hatzimichael, E., A. Dasoula, R. Shah, N. Syed, A. Papoudou-Bai, H.M. Coley, G. Dranitsaris, K.L. Bourantas, J. Stebbing, and T. Crook. 2010. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. European Journal of Haematology 84: 47-51.
45. Hatzimichael, E., G. Dranitsaris, A. Dasoula, L. Benetatos, J. Stebbing, T. Crook, and K.L. Von Bourantas. 2009. Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clinical Lymphoma Myeloma 9: 239-242.
46. Heller, G., W.M. Schmidt, B. Ziegler, S. Holzer, L. Mullauer, M. Bilban, C.C. Zielinski, J. Drach, and S. Zochbauer-Muller. 2008. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Research 68: 44-54.
47. Herman, J.G., F. Latif, Y. Weng, M.I. Lerman, B. Zbar, S. Liu, D. Samid, D.S. Duan, J.R. Gnarra, W.M. Linehan, et al. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 91: 9700-9704.
48. Ho, J.J., J.L. Metcalf, M.S. Yan, P.J. Turgeon, J.J. Wang, M. Chalsev, T.N. Petruzziello-Pellegrini, A.K. Tsui, J.Z. He, H. Dhamko, H.S. Man, G.B. Robb, B.T. Teh, M. Ohh, and P.A. Marsden. 2012. Functional importance of dicer protein in the adaptive cellular response to hypoxia. Journal of Biological Chemistry 287: 29003-29020.
49. Horiuchi, A., T. Hayashi, N. Kikuchi, A. Hayashi, C. Fuseya, T. Shiozawa, and I. Konishi. 2012. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1alpha to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. International Journal of Cancer 131: 1755-1767.
50. Huang, J., Q. Zhao, S.M. Mooney, and F.S. Lee. 2002. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. Journal of Biological Chemistry 277: 39792-39800.
51. Hudson, C.C., M. Liu, G.G. Chiang, D.M. Otterness, D.C. Loomis, F. Kaper, A.J. Giaccia, and R.T. Abraham. 2002. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology 22: 7004-7014.
52. Hur, E., K.Y. Chang, E. Lee, S.K. Lee, and H. Park. 2001. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Molecular Pharmacology 59: 1216-1224.
53. Iliopoulos, O., A.P. Levy, C. Jiang, W.G. Kaelin Jr, and M.A. Goldberg. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proceedings of the National Academy of Sciences of the United States of America 93: 10595-10599.
54. Ishida, M., M. Sunamura, T. Furukawa, M. Akada, H. Fujimura, E. Shibuya, S. Egawa, M. Unno, and A. Horii. 2007. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis. World Journal of Gastroenterology 13: 4593-4597.
55. Ishiguro, M., S. Iida, H. Uetake, S. Morita, H. Makino, K. Kato, Y. Takagi, M. Enomoto, and K. Sugihara. 2007. Effect of combined therapy with low-dose 5-aza-2′-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Annals of Surgical Oncology 14: 1752-1762.
56. Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J.M. Asara, W.S. Lane, and W.G. Kaelin Jr. 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
57. Jaakkola, P., D.R. Mole, Y.M. Tian, M.I. Wilson, J. Gielbert, S.J. Gaskell, A. Kriegsheim, H.F. Hebestreit, M. Mukherji, C.J. Schofield, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
58. Jeong, J.W., M.K. Bae, M.Y. Ahn, S.H. Kim, T.K. Sohn, M.H. Bae, M.A. Yoo, E.J. Song, K.J. Lee, and K.W. Kim. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
59. Jiang, B.H., G. Jiang, J.Z. Zheng, Z. Lu, T. Hunter, and P.K. Vogt. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth & Differentiation 12: 363-369.
60. Jurkowski, T.P., M. Meusburger, S. Phalke, M. Helm, W. Nellen, G. Reuter, and A. Jeltsch. 2008. Human DNMT2 methylates tRNA(Asp) molecules using a DNA methyltransferase-like catalytic mechanism. RNA 14: 1663-1670.
61. Kallio, P.J., I. Pongratz, K. Gradin, J. Mcguire, and L. Poellinger. 1997. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proceedings of the National Academy of Sciences of the United States of America 94: 5667-5672.
62. Kang, S.G., W.H. Lee, Y.H. Lee, Y.S. Lee, and S.G. Kim. 2012. Hypoxia-inducible factor-1alpha inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction. Carcinogenesis 33: 661-669.
63. Kato, H., S. Tamamizu-Kato, and F. Shibasaki. 2004. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. Journal of Biological Chemistry 279: 41966-41974.
64. Ke, Q., and M. Costa. 2006. Hypoxia-inducible factor-1 (HIF-1). Molecular Pharmacology 70: 1469-1480.
65. Kenneth, N.S., S. Mudie, P. Van Uden, and S. Rocha. 2009. SWI/SNF regulates the cellular response to hypoxia. Journal of Biological Chemistry 284: 4123-4131.
66. Kim, M.S., H.J. Kwon, Y.M. Lee, J.H. Baek, J.E. Jang, S.W. Lee, E.J. Moon, H.S. Kim, S.K. Lee, H.Y. Chung, C.W. Kim, and K.W. Kim. 2001. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Medicine 7: 437-443.
67. Koslowski, M., U. Luxemburger, O. Tureci, and U. Sahin. 2011. Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1alpha. Oncogene 30: 876-882.
68. Kothari, S., J. Cizeau, E. Mcmillan-Ward, S.J. Israels, M. Bailes, K. Ens, L.A. Kirshenbaum, and S.B. Gibson. 2003. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22: 4734-4744.
69. Kouzarides, T. 2007. Chromatin modifications and their function. Cell 128: 693-705.
70. Kuroki, T., F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, M. Mori, and C.M. Croce. 2003. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Research 63: 3724-3728.
71. Lando, D., D.J. Peet, J.J. Gorman, D.A. Whelan, M.L. Whitelaw, and R.K. Bruick. 2002. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes & Development 16: 1466-1471.
72. Lando, D., I. Pongratz, L. Poellinger, and M.L. Whitelaw. 2000. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1alpha and the HIF-like factor. Journal of Biological Chemistry 275: 4618-4627.
73. Latif, F., K. Tory, J. Gnarra, M. Yao, F.M. Duh, M.L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320.
74. Law, A.Y., K.P. Lai, C.K. Ip, A.S. Wong, G.F. Wagner, and C.K. Wong. 2008. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Experimental Cell Research 314: 1823-1830.
75. Law, A.Y., and C.K. Wong. 2010a. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Experimental Cell Research 316: 466-476.
76. Law, A.Y., and C.K. Wong. 2010b. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Experimental Cell Research 316: 3425-3434.
77. Lee, Y., C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Radmark, S. Kim, and V.N. Kim. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419.
78. Lei, Z., B. Li, Z. Yang, H. Fang, G.M. Zhang, Z.H. Feng, and B. Huang. 2009. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 4: e7629.
79. Li, E., C. Beard, and R. Jaenisch. 1993. Role for DNA methylation in genomic imprinting. Nature 366: 362-365.
80. Li, L., X. Lin, M. Staver, A. Shoemaker, D. Semizarov, S.W. Fesik, and Y. Shen. 2005. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Research 65: 7249-7258.
81. Lichner, Z., S. Mejia-Guerrero, M. Ignacak, A. Krizova, T.T. Bao, A.H. Girgis, Y.M. Youssef, and G.M. Yousef. 2012. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. American Journal of Pathology 180: 1675-1687.
82. Lippman, Z., and R. Martienssen. 2004. The role of RNA interference in heterochromatic silencing. Nature 431: 364-370.
83. Liu, C.J., M.M. Tsai, P.S. Hung, S.Y. Kao, T.Y. Liu, K.J. Wu, S.H. Chiou, S.C. Lin, and K.W. Chang. 2010. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Research 70: 1635-1644.
84. Livide, G., M.C. Epistolato, M. Amenduni, V. Disciglio, A. Marozza, M.A. Mencarelli, P. Toti, S. Lazzi, T. Hadjistilianou, S. De Francesco, A. D'ambrosio, A. Renieri, and F. Ariani. 2012. Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathology & Oncology Research 18: 703-712.
85. Mahon, P.C., K. Hirota, and G.L. Semenza. 2001. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes & Development 15: 2675-2686.
86. Majumder, P.K., P.G. Febbo, R. Bikoff, R. Berger, Q. Xue, L.M. Mcmahon, J. Manola, J. Brugarolas, T.J. Mcdonnell, T.R. Golub, M. Loda, H.A. Lane, and W.R. Sellers. 2004. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10: 594-601.
87. Makino, Y., R. Cao, K. Svensson, G. Bertilsson, M. Asman, H. Tanaka, Y. Cao, A. Berkenstam, and L. Poellinger. 2001. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554.
88. Maltepe, E., G.W. Krampitz, K.M. Okazaki, K. Red-Horse, W. Mak, M.C. Simon, and S.J. Fisher. 2005. Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta. Development 132: 3393-3403.
89. Manalo, D.J., A. Rowan, T. Lavoie, L. Natarajan, B.D. Kelly, S.Q. Ye, J.G. Garcia, and G.L. Semenza. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659-669.
90. Mansfield, K.D., R.D. Guzy, Y. Pan, R.M. Young, T.P. Cash, P.T. Schumacker, and M.C. Simon. 2005. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metabolism 1: 393-399.
91. Mazure, N.M., E.Y. Chen, K.R. Laderoute, and A.J. Giaccia. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331.
92. Meng, S., J. Cao, L. Wang, Q. Zhou, Y. Li, C. Shen, X. Zhang, and C. Wang. 2012. MicroRNA 107 Partly Inhibits Endothelial Progenitor Cells Differentiation via HIF-1beta. PLoS One 7: e40323.
93. Metzen, E., J. Zhou, W. Jelkmann, J. Fandrey, and B. Brune. 2003. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Molecular Biology of the Cell 14: 3470-3481.
94. Michishita, E., J.Y. Park, J.M. Burneskis, J.C. Barrett, and I. Horikawa. 2005. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Molecular Biology of the Cell 16: 4623-4635.
95. Mie Lee, Y., S.H. Kim, H.S. Kim, M. Jin Son, H. Nakajima, H. Jeong Kwon, and K.W. Kim. 2003. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300: 241-246.
96. Min, L., Q. Chen, S. He, S. Liu, and Y. Ma. 2012. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed by RNA interference of HIF-1alpha expression. Molecular Medicine Report 5: 228-232.
97. Miranda, T.B., and P.A. Jones. 2007. DNA methylation: the nuts and bolts of repression. Journal of Cellular Physiology 213: 384-390.
98. Mizuno, T., M. Nagao, Y. Yamada, M. Narikiyo, M. Ueno, M. Miyagishi, K. Taira, and Y. Nakajima. 2006. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Therapy 13: 131-140.
99. Murai, M., M. Toyota, H. Suzuki, A. Satoh, Y. Sasaki, K. Akino, M. Ueno, F. Takahashi, M. Kusano, H. Mita, K. Yanagihara, T. Endo, Y. Hinoda, T. Tokino, and K. Imai. 2005. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clinical Cancer Research 11: 1021-1027.
100. Newell-Price, J., A.J. Clark, and P. King. 2000. DNA methylation and silencing of gene expression. Trends in Endocrinology & Metabolism 11: 142-148.
101. Okami, J., D.M. Simeone, and C.D. Logsdon. 2004. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Research 64: 5338-5346.
102. Okano, M., D.W. Bell, D.A. Haber, and E. Li. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.
103. Pinto, A., and V. Zagonel. 1993. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 7(Suppl 1): 51-60.
104. Place, T.L., M.P. Fitzgerald, S. Venkataraman, S.U. Vorrink, A.J. Case, M.L. Teoh, and F.E. Domann. 2011. Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells. PLoS One 6: e14617.
105. Ponting, C.P., P.L. Oliver, and W. Reik. 2009. Evolution and functions of long noncoding RNAs. Cell 136: 629-641.
106. Qian, D.Z., S.K. Kachhap, S.J. Collis, H.M. Verheul, M.A. Carducci, P. Atadja, and R. Pili. 2006. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Research 66: 8814-8821.
107. Ratcliffe, P.J. 2007. HIF-1 and HIF-2: working alone or together in hypoxia? Journal of Clinical Investigation 117: 862-865.
108. Ravi, R., B. Mookerjee, Z.M. Bhujwalla, C.H. Sutter, D. Artemov, Q. Zeng, L.E. Dillehay, A. Madan, G.L. Semenza, and A. Bedi. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes & Development 14: 34-44.
109. Richard, D.E., E. Berra, E. Gothie, D. Roux, and J. Pouyssegur. 1999. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. Journal of Biological Chemistry 274: 32631-32637.
110. Robert, M.F., S. Morin, N. Beaulieu, F. Gauthier, I.C. Chute, A. Barsalou, and A.R. Macleod. 2003. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nature Genetics 33: 61-65.
111. Salceda, S., and J. Caro. 1997. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. Journal of Biological Chemistry 272: 22642-22647.
112. Sang, N., J. Fang, V. Srinivas, I. Leshchinsky, and J. Caro. 2002. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Molecular and Cellular Biology 22: 2984-2992.
113. Sasakawa, Y., Y. Naoe, T. Noto, T. Inoue, T. Sasakawa, M. Matsuo, T. Manda, and S. Mutoh. 2003. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochemical Pharmacology 66: 897-906.
114. Saxonov, S., P. Berg, and D.L. Brutlag. 2006. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proceedings of the National Academy of Sciences of the United States of America 103: 1412-1417.
115. Schindl, M., S.F. Schoppmann, H. Samonigg, H. Hausmaninger, W. Kwasny, M. Gnant, R. Jakesz, E. Kubista, P. Birner, and G. Oberhuber. 2002. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clinical Cancer Research 8: 1831-1837.
116. Schmitt, A.M., S. Schmid, T. Rudolph, M. Anlauf, C. Prinz, G. Kloppel, H. Moch, P.U. Heitz, P. Komminoth, and A. Perren. 2009. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine Related Cancer 16: 1219-1227.
117. Semenza, G.L. 2004. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. Journal Applied Physiology 96: 1173-1177. discussion 1170-1172.
118. Semenza, G.L., B.H. Jiang, S.W. Leung, R. Passantino, J.P. Concordet, P. Maire, and A. Giallongo. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Journal of Biological Chemistry 271: 32529-32537.
119. Sivridis, E., A. Giatromanolaki, K.C. Gatter, A.L. Harris, and M.I. Koukourakis. 2002. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95: 1055-1063.
120. Song, T., X. Zhang, C. Wang, Y. Wu, W. Cai, J. Gao, and B. Hong. 2012. MiR-138 suppresses expression of hypoxia-inducible factor 1alpha (HIF-1alpha) in clear cell renal cell carcinoma 786-O cells. Asian Pacific Journal of Cancer Prevention 12: 1307-1311.
121. Sprenger, S.H., J.M. Gijtenbeek, P. Wesseling, R. Sciot, F. Van Calenbergh, M. Lammens, and J.W. Jeuken. 2001. Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. Journal of Neurooncology 52: 241-247.
122. Stephen, J.K., K.M. Chen, M. Raitanen, S. Grenman, and M.J. Worsham. 2009. DNA hypermethylation profiles in squamous cell carcinoma of the vulva. International Journal of Gynecological Pathology 28: 63-75.
123. Stiehl, D.P., D.M. Fath, D. Liang, Y. Jiang, and N. Sang. 2007. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. Cancer Research 67: 2256-2264.
124. Suzuki, M., F. Shinohara, and H. Rikiishi. 2008. Zebularine-induced reduction in VEGF secretion by HIF-1alpha degradation in oral squamous cell carcinoma. Molecular Medicine Report 1: 465-471.
125. Taguchi, A., K. Yanagisawa, M. Tanaka, K. Cao, Y. Matsuyama, H. Goto, and T. Takahashi. 2008. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Research 68: 5540-5545.
126. Talks, K.L., H. Turley, K.C. Gatter, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, and A.L. Harris. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues,
127. Tanimoto, K., Y. Makino, T. Pereira, and L. Poellinger. 2000. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO Journal 19: 4298-4309.
128. Thiagalingam, S., K.H. Cheng, H.J. Lee, N. Mineva, A. Thiagalingam, and J.F. Ponte. 2003. Histone deacetylases: unique players in shaping the epigenetic histone code. Annals of the New York Academy of Sciences 983: 84-100.
129. Tian, H., S.L. Mcknight, and D.W. Russell. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes & Development 11: 72-82.
130. Valencia-Sanchez, M.A., J. Liu, G.J. Hannon, and R. Parker. 2006. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes & Development 20: 515-524.
131. Valera, V.A., B.A. Walter, W.M. Linehan, and M.J. Merino. 2011. Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. Journal of Cancer 2: 515-526.
132. Volland, S., W. Kugler, L. Schweigerer, J. Wilting, and J. Becker. 2009. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. International Journal of Cancer 125: 2049-2057.
133. Vordermark, D. 2002. Expression of hypoxia-inducible factor-1alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 94: 2317-2318. author reply 2318-2319.
134. Walczak-Drzewiecka, A., M. Ratajewski, L. Pulaski, and J. Dastych. 2010. DNA methylation-dependent suppression of HIF1A in an immature hematopoietic cell line HMC-1. Biochemical and Biophysical Research Communications 391: 1028-1032.
135. Walsh, C.P., J.R. Chaillet, and T.H. Bestor. 1998. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nature Genetics 20: 116-117.
136. Wang, F.S., C.J. Wang, Y.J. Chen, P.R. Chang, Y.T. Huang, Y.C. Sun, H.C. Huang, Y.J. Yang, and K.D. Yang. 2004. Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1alpha and VEGF-A expression in shock wave-stimulated osteoblasts. Journal of Biological Chemistry 279: 10331-10337.
137. Wang, G.L., and G.L. Semenza. 1995. Purification and characterization of hypoxia-inducible factor 1. Journal of Biological Chemistry 270: 1230-1237.
138. Weber, M., and D. Schubeler. 2007. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Current Opinion in Cell Biology 19: 273-280.
139. Wenger, R.H. 2002. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB Journal 16: 1151-1162.
140. Wenger, R.H., I. Kvietikova, A. Rolfs, G. Camenisch, and M. Gassmann. 1998. Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. European Journal of Biochemistry 253: 771-777.
141. Yamakuchi, M., S. Yagi, T. Ito, and C.J. Lowenstein. 2011. MicroRNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One 6: e20291.
142. Yang, X.J., and E. Seto. 2003. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Current Opinion in Genetics & Development 13: 143-153.
143. Yu, F., S.B. White, Q. Zhao, and F.S. Lee. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 98: 9630-9635.
144. Zelzer, E., Y. Levy, C. Kahana, B.Z. Shilo, M. Rubinstein, and B. Cohen. 1998. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO Journal 17: 5085-5094.
145. Zhang, Y., H.H. Ng, H. Erdjument-Bromage, P. Tempst, A. Bird, and D. Reinberg. 1999. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & Development 13: 1924-1935.
146. Zhou, H., W. Fei, Y. Bai, S. Zhu, E. Luo, K. Chen, and J. Hu. 2012. RNA interference-mediated downregulation of hypoxia-inducible factor-1alpha inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo. European Journal of Cancer Prevention 21: 289-299.
147. Zundel, W., C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A.R. Gottschalk, H.E. Ryan, R.S. Johnson, A.B. Jefferson, D. Stokoe, and A.J. Giaccia. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes & Development 14: 391-396.